Collectively, our data provide novel mechanistic insights into the complex interplay between endothelial dysfunction and complement activation as the underlying cause of lung injury induced by S1 protein and suggests C3a and C3aR as potential promising therapeutic targets for the clinical management of COVID-19 patients. Here, PSMD1 is linked to COVID-19.